Research programme: peptide therapeutics - Genentech/PeptiDream
Latest Information Update: 28 Dec 2024
At a glance
- Originator PeptiDream
- Developer Genentech; PeptiDream
- Class Macrocyclic compounds; Peptides
- Mechanism of Action Proto-oncogene protein c-met modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for research development in Unspecified in Japan
- 28 Dec 2024 No recent reports of development identified for research development in Unspecified in USA
- 07 Dec 2022 Early research is still ongoing for Undisclosed indication in Japan and USA (PeptiDream pipeline, December 2022)